Non-alcoholic fatty liver disease (NAFLD) is one of the most common liver diseases
worldwide, with a global prevalence of approximately 30%. However, the prevalence of …

Non-alcoholic fatty liver disease (NAFLD), which is emerging as a major public health issue
worldwide, is characterized by a wide spectrum of liver disorders, ranging from simple fat …

The multimodal activities of farnesoid X receptor (FXR) agonists make this class an attractive
option to treat nonalcoholic steatohepatitis. The safety and efficacy of tropifexor, an FXR …

Background & Aims Patients with non-alcoholic fatty liver disease (NAFLD) and significant
fibrosis (fibrosis stage≥ 2) are candidates for pharmacological trials. The aim of this study …

Background & Aims Liver fibrosis is a key prognostic determinant for clinical outcomes in
non-alcoholic steatohepatitis (NASH). Current scoring systems have limitations, especially in …

Nonalcoholic fatty liver disease (NAFLD) is increasingly prevalent worldwide and becoming
a major cause of liver disease-related morbidity and mortality. The presence of liver fibrosis …

2022 was a proficuous year in both the nonalcoholic fatty liver disease (NAFLD) and obesity
fields. Pharmacological treatment for obesity and NAFLD is moving forward, with the …

In the last 20 years, noninvasive serum biomarkers to identify liver fibrosis in patients with
non-alcoholic fatty liver disease (NAFLD) have been developed, validated against liver …

Background By identifying individuals at high risk for non-alcoholic fatty liver disease
(NAFLD), interventional programs could be targeted more effectively. Some studies have …

Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease,
affecting approximately 25% of the general population worldwide, and is forecasted to …